Pilot study of first-in-class antimitochondrial metabolism agent, CPI-613, as salvage monotherapy for small cell lung cancer.

e20100Background: Small cell lung cancer (SCLC) is a common lung cancer which presents with extensive stage disease at time of diagnosis in two-thirds of patients. For treatment of advanced disease...